Use of Gevokizumab in Patients with Behcet's Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study

Tugal-Tutkun, Ilknur; PAVESIO, Carlos; DE CORDOUE, Agnes; BERNARD-POENARU, Oana; Gül, Ahmet

doi:10.1080/09273948.2017.1421233

Use of Gevokizumab in Patients with Behcet's Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study

Tugal-Tutkun I., PAVESIO C., DE CORDOUE A., BERNARD-POENARU O., Gül A.

OCULAR IMMUNOLOGY AND INFLAMMATION, cilt.26, sa.7, ss.1023-1033, 2018 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 26 Sayı: 7
Basım Tarihi: 2018
Doi Numarası: 10.1080/09273948.2017.1421233
Dergi Adı: OCULAR IMMUNOLOGY AND INFLAMMATION
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1023-1033
Anahtar Kelimeler: Behcet's disease, gevokizumab, interleukin-1 beta, ocular exacerbation, uveitis, XOMA 052, INTERLEUKIN-1-BETA, STANDARDIZATION, RECOMMENDATIONS, POLYMORPHISMS, MULTICENTER, ADALIMUMAB, MANAGEMENT, CYTOKINES, DIAGNOSIS
İstanbul Üniversitesi Adresli: Evet

Özet

Purpose: The purpose of this article is to demonstrate the superiority of gevokizumab as compared to placebo, on top of current standard of care, in reducing the risk of Behcet's disease uveitis (BDU) exacerbations.